reduced-dose PTCy for graft vs host disease

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 26 Nov 2024: Trial registered, NCT06705062
  2. 1 Jan 2025: Trial started, NCT06705062

The trials

NCT06705062: Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation

State
Under way
Phase
Phase 3
People
316 planned
Started
1 Jan 2025
Primary completion
1 Dec 2027
Arms
Reduced dose of post-transplantation cyclophosphamide
Results
None posted
  1. 26 Nov 2024: Trial registered
  2. 1 Jan 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.